Verrica Pharmaceuticals Inc. announced a strong performance for the second quarter of 2025, characterized by a significant increase in demand for their product, YCANTH®. The company reported a record 13,434 dispensed applicator units during this period, marking a sequential growth of 32.8% compared to the first quarter of 2025. This growth rate was nearly double the previous quarter's increase of 16.7% over the fourth quarter of 2024. The company attributes this success to a more focused commercial strategy, which has resulted in a rising number of dermatology and pediatric physician practices prescribing YCANTH. Additionally, Verrica highlighted the receipt of an $8 million milestone payment from their Japanese development partner, Torii Pharmaceutical, in recognition of the initiation of a global Phase 3 program for common warts. The milestone payment is part of a larger collaboration, which also includes a potential $10 million payment upon regulatory approval of YCANTH in Japan for molluscum and contributions to the global Phase 3 clinical program. These financial developments, along with strong sales growth, are key pillars supporting Verrica's business strategy. The company is also looking forward to providing an update on their development strategy for VP-315, a product candidate for basal cell carcinoma. CEO Jayson Rieger expressed pride in the company's growth, emphasizing the effectiveness of their commercial and patient access strategies, as well as their robust distribution network.